linjc16/ctgov huggingface dataset:
Long-term Assessment of Organ Functions Among Survivors of Severe Acute Respiratory Syndrome

Study Overview
=================
Brief Summary
-----------------
SARS-CoV has caused severe epidemic respiratory disease in human populations. By July 2003, a total of 8,096 probable cases of SARS had been reported including 774 deaths in 27 countries, around one-third of which were health care workers (HCWs). Previous studies have been reported about long-term impacts of SARS infection, including lung function deficiency, steroid-induced osteonecrosis, reduced exercise capacity, and impairment in health-related quality of life (HRQoL). HCWs, especially nurses, have been reported to experience greater psychological distress, particularly increased levels of posttraumatic stress symptomatology (PTSS). But the very complex impacts of this fatal infection on HCWs have not been fully elucidated. It is thus important to follow these occupational patients to detect and manage multi-organ sequelae and functional impairment.

Official Title
-----------------
The 15-year Impact of Severe Acute Respiratory Syndrome on Organ Functions, Exercise Capacity, and Quality of Life in Survivors.

Conditions
-----------------
SARS Virus, Long-Term Survivors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Health care workers who were working at Peking University People's Hospital during the SARS epidemic in 2002-2003 Exclusion Criteria: Refusal to continue the study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SARS survivors<br>First-line HCWs infected during the SRAS-CoV pandemic in Peking University People's Hospital, China. Diagnose was further confirmed by SARS-CoV seropositive results. | |
| Controls<br>Coworkers of the infected HCWs, who also exposed to SARS patients or specimens. Infection was further excluded by SARS-CoV seronegative results. Healthy controls matched for age, sex and disease condition, but without exposures to SARS virus. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause disability | Disabilities arising from physical injuries and/or mental stresses | Evaluations would be finished within 90 days after enrollment. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiopulmonary function | The interrelationship between the workings of the heart and lung organs would be assessed by assessed by 6MWT (6-min walk test) | Evaluations would be finished within 90 days after enrollment. | 
| Life Life quaities mental distress | Quality of life would be assessed by the Medical Outcomes Study 36-item short form version 2 (SF-36) | Evaluations would be finished within 90 days after enrollment. |
Continuous Glucose Monitoring Following Hospital Discharge

Study Overview
=================
Brief Summary
-----------------
In this 12-week prospective observational cohort study, hospitalized insulin-requiring patients with T2D will receive a Dexcom continuous glucose monitor (CGM) to wear post-hospital discharge. Patients will complete surveys assessing patient-reported outcomes prior to CGM use and following completion of the study. CGM data will be captured by the patient smartphone app and analyzed. Patients will receive personalized CGM targets and alerts for hyperglycemia and hypoglycemia. Customized reports/ decision support will be sent to the usual diabetes provider. The initial observational cohort study design will be followed by an extension phase of 12 weeks in which data on continuation of use and glucose control will be collected but no further reports will be communicated to providers.

Official Title
-----------------
Effect of Continuous Glucose Monitoring Following Hospital Discharge of Patients With Type 2 Diabetes

Conditions
-----------------
Type 2 Diabetes

Intervention / Treatment
-----------------
* Device: DexCom G6


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 Diabetes Basal insulin use >10 units per day Hemoglobin A1c >8.0% Smartphone compatible with Clarity App Age ≥18 years Exclusion Criteria: Type 1 DM Inability to consent Pregnancy Prisoners Discharge to skilled nursing facility

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dexcom CGM<br> | Device: DexCom G6<br>* Wearable continuous glucose monitor<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent change in TIR 70-180 mg/dl |  | 12 weeks | 
| The proportion of patients with % wear time >70% will be reported. | The proportion of patients with % wear time >70% will be reported. | 12 weeks | 
| Change in DTSQc scores | The Diabetes Treatment Satisfaction Questionnaire (change) will be administered at enrollment and at 12 weeks. Total scores will be compared. The DTSQc compares the experience of the current treatment with the experience of the treatment before initiation of the study. Scores range from +3 (much more satisfied now) to -3 (much less satisfied now), with 0 (midpoint) representing no change. Higher scores on the DTSQ total score indicate higher treatment satisfaction, and lower scores indicate lower treatment satisfaction. | 12 weeks |
Retrospective Study on Sexual Health in the Aftermath of an Obstetric Lesion of the Anal Sphincter

Study Overview
=================
Brief Summary
-----------------
Lesions of the anal sphincter complicate 0.8% of childbirth in France. The sexual health of patients following this type of lesion is little studied, there are only about twenty articles on the subject. The objective of this search is to study of the obstetric lesions of the anal sphincter

Official Title
-----------------
Retrospective Study on Sexual Health in the Aftermath of an Obstetric Lesion of the Anal Sphincter

Conditions
-----------------
Lesions of the Anal Sphincter

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Adult woman (≥18 years old) Patient who gave birth at term to a child born living in the maternity hospitals of Strasbourg University Hospital between 01/01/2019 and 12/31/2019 Single pregnancy 3rd degree or 4th degree perineal tear Intact perineum (control group) Good understanding of French orally Patient accepting to participate in the satisfaction telephone interview and not having expressed her opposition to the reuse of her data for the purposes of this research. Exclusion criteria: Subject having expressed opposition to participating in the study Cesarean delivery Multiple pregnancy Premature delivery stillborn child impossibility of providing the subject with enlightened information (subject in an emergency situation, difficulties in understanding the subject, etc.) Subject under safeguard of justice Subject under guardianship or guardianship Subject under guardianship, curatorship or safeguard of justice

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective study of obstetric lesions of the anal sphincter |  | Files analysed retrospectively from January 01, 2019 to December 31, 2019 will be examined] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lesions of the anal sphincter, Anal sphincter, Sexual health
GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal Insulin

Study Overview
=================
Brief Summary
-----------------
To evaluate the effectiveness of Glucobay when combined with a basal insulin under daily-life treatment conditions in a large sample of Korean patients.

Official Title
-----------------
Combined Use of a Basal Insulin and Glucobay For Reducing PPG to End Diabetes Progress

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: Acarbose (Glucobay, BAYG5421)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed written informed consent Age ≥ 18 years Diagnosed of type 2 diabetes for at least 6 months prior to enrollment Patients treated with stable dose of a basal insulin (insulin glargine or insulin detemir) at least 2 months HbA1C≥7.5 and ≤10.0% Exclusion Criteria: Exclusion criteria must be read in conjunction with the local product information

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Acarbose (Glucobay, BAYG5421)<br>* Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in HbA1c |  | After 20 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration and dose of acarbose treatment |  | After 20 weeks | 
| Postprandial Blood Glucose |  | After 20 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acarbose/Glucobay®, Basal insulin, PPG (Postprandial Glycaemia)
Diagnosis of Macrophage Coronary Plaque by Optical Tomographic Imaging

Study Overview
=================
Brief Summary
-----------------
This study evaluated optimal macrophage diagnosis algorithm through comparative analysis between coronary artery, OCT image, and IVUS, and improve a diagnosis rate of vulnerable coronary plaque accompanied with macrophage infiltration.

Official Title
-----------------
Diagnosis of Macrophage Coronary Plaque by Optical Tomographic Imaging : A Comparative Study With Coronary Artery of the Transplanted or Autopsy Heart

Conditions
-----------------
Atherosclerotic Plaque

Intervention / Treatment
-----------------
* Procedure: The heart subject will undergo OCT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 and above Patients who are to receive heart transplantation Patients or their legal representatives who gave a prior written consent Exclusion Criteria: Impossible to OCT and IVUS analysis due to severe coronary stenosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| isolated heart from heart transplantation<br> | Procedure: The heart subject will undergo OCT<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ROC curve of diagnosis | Receiver Operating Characteristic curve of diagnosis through existing NSD(normalized standard deviation)-based method and developed algorithm in the diagnosis of coronary plaque accompanied with macrophage infiltration | within 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fibrin accumulation |  | within 48 hours | 
| neoatherosclerosis |  | within 48 hours | 
| elastic lamia |  | within 48 hours | 
| cholesterol crystal |  | within 48 hours | 
| microcalcification |  | within 48 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
macrophage, vulnerable coronary plaque
Clinical Aspect of Erosive Pustular Dermatosis of the Leg

Study Overview
=================
Brief Summary
-----------------
Erosive pustular dermatosis of the leg is a fairlyrecent clinical entity that was described the first time in 1987. Diagnosis of erosive pustular dermatosis of the leg is made on clinical grounds. It presents as non-follicular pustules of variable size and numbers that rapidly give way to erosions and crusts on one or both legs, and which are found in particular on the anterior aspect of the middle third of the leg (. The lesions are of chronic progression, despite topical therapy. Erosive pustular dermatosis of the leg is seen in elderly patients, mainly female, and may be associated with chronic venous insufficiency or cutaneous atrophy. In the absence of specific criteria and because of the existence of misleading clinical forms, diagnosis is based upon exclusion.

Detailed Description
-----------------
The primary objective of this investigation was to describe the different clinical aspects of cases of Erosive pustular dermatosis of the leg.

Official Title
-----------------
Clinical Aspect of Erosive Pustular Dermatosis of the Leg

Conditions
-----------------
Erosive Pustular Dermatosis of the Leg

Intervention / Treatment
-----------------
* Other: Clinical examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - non-follicular pustules and multiple erosions on one or both legs showing no evidence of improvement after application of compression in the event of clinical signs of chronic venous insufficiency and showing no improvement following treatment with local and/or systemic antibacterial therapy, fungal samples from the pustules negative on direct examination, negative direct immunofluorescence results for biopsy samples (taken from around the lesion) Exclusion Criteria: - age < 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with erosive pustular dermatosis of the leg<br> | Other: Clinical examination<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lesions location | Anterior or posterior leg face | Day 0 | 
| number of lesions | Less than 10 erosions, between 10 and 50 erosions and more than 50 erosions | Day 0 | 
| Presence of chronic venous insufficiency | Diagnosis based on the CEAP 2004 Score (Eklöf B, Rutherford RB, Bergan JJ, Carpentier PH, GloviczkiP, Kistner RL, et al. Revision of the CEAP classification forchronic venous disorders: consensus statement. J Vasc Surg2004;40:1248-52) | Day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Erosive pustular dermatosis of the leg, Erosive pustular dermatosis of the scalp, Venous insufficiency
Construction of a Database for TTP

Study Overview
=================
Brief Summary
-----------------
Information about patients was collected by reviewing the Hitech case system and telephone and outpatient follow-up, and the case database was constructed by Epidata software. The sample size is expected to be 200 cases, the participating hospital is the First Affiliated Hospital of Soochow University, and the study time frame is from Oct 20, 2022, to Oct 20, 2027. The observation indexes of the study include the basic information of patients' age and gender and the clinical related data of thrombotic thrombocytopenic purpura.

Official Title
-----------------
Construction of a Database for Thrombotic Thrombocytopenic Purpura

Conditions
-----------------
TTP - Thrombotic Thrombocytopenic Purpura

Intervention / Treatment
-----------------
* Other: collection data


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Subjects diagnosed with severe ADAMTS13 deficiency, defined as ADAMTS13 activity <10%, documented in the patient's medical history or at screening. Exclusion Criteria: - The investigator considers the subject unable or unwilling to cooperate with the study procedures.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TTP<br>TTP patients | Other: collection data<br>* collection data<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with stroke | Stroke was assessed with MRI imaging. | 5 years from the time of entering the database. |
Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis

Study Overview
=================
Brief Summary
-----------------
The primary objective is to assess the efficacy and safety of etanercept 50 mg administered once weekly in subjects with psoriasis over 12 weeks.

Official Title
-----------------
A Multicenter, Parallel, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Moderate to Severe Plaque Psoriasis

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Drug: Etanercept


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Adults greater than or equal to 18 years of age with clinically stable plaque psoriasis involving greater than or equal to 10% of the body surface and a minimum Psoriasis Area and Severity Index (PASI) score of 10 at screening. -Failure to respond to, or have a contraindication to, or intolerant to at least 1 of the following systemic or phototherapies at an adequate dose of sufficient duration: Methotrexate (MTX), Acitretin, Cyclosporine, Ultraviolet A (UVA), Ultraviolet B (UVB), Psoralen and Ultraviolet A (PUVA), Fumarate Exclusion Criteria: -Previous treatment with etanercept, antibody to TNF or other TNF inhibitors. -Active guttate, erythrodermic, or pustular psoriasis at the time of the screening or baseline.&#xd;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Etanercept|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary efficacy endpoint is the PASI 75 response at week 12. PASI 75 is defined as a 75% or greater improvement in PASI score from baseline. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The secondary efficacy endpoints will include but not limited to: PASI 50, PASI 75 (at visit other than week 12, PASI 90, PASI score PGA of 0 or 1 (clear or minimal, Patient global assessment of psoriasis, DLQI, |  |  | 
| EQ5D, FACIT-F. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Psoriasis
Metabolomic Study for Localized Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
Prostate cancer is a common disease in men treated using surgery, radiation therapy and/or hormonal therapy. Clinical prognosis relates to stage and grade of disease. Recent advances in omic analysis may offer additional information to the physician about prognosis and radiation response. We propose to establish a protocol to incorporate omic analysis into the evaluation and treatment of patients with prostate cancer.

Official Title
-----------------
A Pilot Study to Establish a Standardized Protocol for Omic Analysis of Patients With Clinically Localized Prostate Cancer Receiving Radiation Therapy

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Radiation: Radiation Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males who are older than 18 years old, with clinically localized prostate cancer are receiving radiation therapy Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Prostate Cancer Patients<br>Prostate cancer patients who underwent radiation therapy | Radiation: Radiation Therapy<br> <br> * Other names: Prostate stereotactic body radiation therapy (SBRT) and intensive modulated radiation therapy (IMRT) or the combination of both (boost);|
| Healthy control<br>age-matched male who has no known prostate cancer | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| molecular changes in biofluid |  | 5 years |